AZAD, a privately held company, was established in 2000 to exclusively handle Cilag’s global sales and marketing activities of Active Pharmaceutical Ingredients (APIs). Soon after, AZAD began to diversify its field of expertise in order to broaden its offerings and extend its presence in the healthcare industry. Notably, AZAD concentrates on the following major areas;
Active Pharmaceutical Ingredients
AZAD PHARMACEUTICAL INGREDIENTS (Schaffhausen/Switzerland)
Develops non infringing APIs through proprietary development and partnerships.
AZAD PHARMA (Bern/Switzerland)
Develops non infringing Finished Drug products.
Develops and offers modified, value added drug products.
AZAD has a broad reach with offices in Canada, Switzerland, Armenia, and China, and has immediate access to all potential clients in the Americas, Europe, Asia, Middle East, and CIS region. With high investment in personnel AZAD also assures effective marketing gathering activities that translate into successful projects.
AZAD continuously invests in API development working closely with all its partners worldwide. Our mandate is clear: develop high barrier, non infringing APIs in cGMP conditions. To date, AZAD has developed and participated in several court challenges resulting in increased revenues for our clients. In addition, AZAD entered into partnership with Yonsung Fine Chemicals of Korea in 2003 to distribute Latanoprost exclusively around the world. This partnership produced collaboration on all of Yonsung’s additional APIs. On track with its goals, AZAD began partnering with proven European/Chinese/Indian companies for worldwide development, manufacturing and representation of APIs.
Finished Dosage Forms
In 2005, AZAD decided to further advance its reach and scope by developing quality and value added generic Drug Product forms in the Injectable and Ophthalmic fields. Today, AZAD proudly offers several worldwide dossiers. In addition, AZAD is also developing value added drug products such as preservative free ophthalmics and oncology products with reduced side effects.